Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer

Journal of Medicinal Chemistry

Volumn 56, Issue 12, 2013, Pages 4880-4898

  Purushottamachar, Puranik ^a   Godbole, Abhijit M ^a,e   Gediya, Lalji K ^a   Martin, Marlena S ^a   Vasaitis, Tadas S ^a,b   Kwegyir Afful, Andrew K ^a   Ramalingam, Senthilmurugan ^a   Ates Alagoz, Zeynep ^c,d   Njar, Vincent C O ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND EASTERN SHORE   (United States)

^c ANKARA UNIVERSITY   (Turkey)

^d UNIVERSITY OF THE SCIENCES   (United States)

^e ST BARNABAS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(HYDROXIMINO) 17 (1H BENZIMIDAZOL 1 YL)]ANDROSTA 4,16 DIENE; 3BETA [(1H IMIDAZOLE 1 CARBOXYLATE) 17 (1H BENZIMIDAZOL 1 YL)]ANDROSTA 5,16 DIENE; 3BETA [(PYRIDINE 4 CARBOXYLATE) 17 (1H BENZIMIDAZOL 1 YL)]ANDROSTA 5,16 DIENE; ANDROGEN RECEPTOR; GALETERONE; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; DOWN REGULATION; DRUG STRUCTURE; DRUG TARGETING; HUMAN; HUMAN CELL; MALE; PROSTATE CANCER; STRUCTURE ACTIVITY RELATION;

ANDROSTADIENES; BENZIMIDAZOLES; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; DRUG DESIGN; HUMANS; MALE; MOLECULAR TARGETED THERAPY; PROSTATIC NEOPLASMS; PROTEOLYSIS; RECEPTORS, ANDROGEN; STEROID 17-ALPHA-HYDROXYLASE; TRANSCRIPTIONAL ACTIVATION;

EID: 84879579619     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400048v     Document Type: Article

References (78)

1. Chen, C. D.; Welsbie, D. S.; Tran, C.; Baek, S. H.; Chen, R.; Vessella, R.; Rosenfeld, M. G.; Sawyers, C. L. Molecular determinants of resistance to antiandrogen therapy Nat. Med. 2004, 10 (1) 33-39
2. Chen, Y.; Clegg, N. J.; Scher, H. I. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target Lancet Oncol. 2009, 10 (10) 981-991
3. Cheng, H.; Snoek, R.; Ghaidi, F.; Cox, M. E.; Rennie, P. S. Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression Cancer Res. 2006, 66 (21) 10613-10620
4. Snoek, R.; Cheng, H.; Margiotti, K.; Wafa, L. A.; Wong, C. A.; Wong, E. C.; Fazli, L.; Nelson, C. C.; Gleave, M. E.; Rennie, P. S. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors Clin. Cancer Res. 2009, 15 (1) 39-47
5. Vasaitis, T. S.; Njar, V. C. O. Novel, potent anti-androgens of therapeutic potential: recent advances and promising developments Future Med. Chem. 2010, 2 (4) 667-680
6. Montgomery, R. B.; Mostaghel, E. A.; Vessella, R.; Hess, D. L.; Kalhorn, T. F.; Higano, C. S.; True, L. D.; Nelson, P. S. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth Cancer Res. 2008, 68 (11) 4447-4454
7. Mostaghel, E. A.; Nelson, P. S. Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications Best Pract. Res., Clin. Endocrinol. Metab. 2008, 22 (2) 243-258
8. Stanbrough, M.; Bubley, G. J.; Ross, K.; Golub, T. R.; Rubin, M. A.; Penning, T. M.; Febbo, P. G.; Balk, S. P. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer Cancer Res. 2006, 66 (5) 2815-2825
9. Vasaitis, T.; Bruno, R. D.; Njar, V. C. O. CYP17 inhibitors for prostate cancer therapy J. Steroid Biochem. Mol. Biol. 2010, 2011, 23-31
10. Clegg, N. J.; Wongvipat, J.; Joseph, J. D.; Tran, C.; Ouk, S.; Dilhas, A.; Chen, Y.; Grillot, K.; Bischoff, E. D.; Cai, L.; Aparicio, A.; Dorow, S.; Arora, V.; Shao, G.; Qian, J.; Zhao, H.; Yang, G.; Cao, C.; Sensintaffar, J.; Wasielewska, T.; Herbert, M. R.; Bonnefous, C.; Darimont, B.; Scher, H. I.; Smith-Jones, P.; Klang, M.; Smith, N. D.; De Stanchina, E.; Wu, N.; Ouerfelli, O.; Rix, P. J.; Heyman, R. A.; Jung, M. E.; Sawyers, C. L.; Hager, J. H. ARN-509: a novel antiandrogen for prostate cancer treatment Cancer Res. 2012, 72 (6) 1494-1503
11. Jung, M. E.; Ouk, S.; Yoo, D.; Sawyers, C. L.; Chen, C.; Tran, C.; Wongvipat, J. Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC) J. Med. Chem. 2010, 53 (7) 2779-2796
12. Tran, C.; Ouk, S.; Clegg, N. J.; Chen, Y.; Watson, P. A.; Arora, V.; Wongvipat, J.; Smith-Jones, P. M.; Yoo, D.; Kwon, A.; Wasielewska, T.; Welsbie, D.; Chen, C. D.; Higano, C. S.; Beer, T. M.; Hung, D. T.; Scher, H. I.; Jung, M. E.; Sawyers, C. L. Development of a second-generation antiandrogen for treatment of advanced prostate cancer Science 2009, 324 (5928) 787-790
13. Bryce, A.; Ryan, C. J. Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor Clin. Pharmacol. Ther. 2012, 91 (1) 101-108
14. Kaku, T.; Hitaka, T.; Ojida, A.; Matsunaga, N.; Adachi, M.; Tanaka, T.; Hara, T.; Yamaoka, M.; Kusaka, M.; Okuda, T.; Asahi, S.; Furuya, S.; Tasaka, A. Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer Bioorg. Med. Chem. 2011, 19 (21) 6383-6399
15. Bruno, R. D.; Vasaitis, T. S.; Gediya, L. K.; Purushottamachar, P.; Godbole, A. M.; Ates-Alagoz, Z.; Brodie, A. M.; Njar, V. C. Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model Steroids 2011, 76 (12) 1268-1279
16. Mukherji, D.; Pezaro, C. J.; De-Bono, J. S. MDV3100 for the treatment of prostate cancer Expert Opin. Invest. Drugs 2012, 21 (2) 227-233
17. Reid, A. H.; Attard, G.; Danila, D. C.; Oommen, N. B.; Olmos, D.; Fong, P. C.; Molife, L. R.; Hunt, J.; Messiou, C.; Parker, C.; Dearnaley, D.; Swennenhuis, J. F.; Terstappen, L. W.; Lee, G.; Kheoh, T.; Molina, A.; Ryan, C. J.; Small, E.; Scher, H. I.; de Bono, J. S. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate J. Clin. Oncol. 2010, 28 (9) 1489-1495
18. Hu, R.; Lu, C.; Mostaghel, E. A.; Yegnasubramanian, S.; Gurel, M.; Tannahill, C.; Edwards, J.; Isaacs, W. B.; Nelson, P. S.; Bluemn, E.; Plymate, S. R.; Luo, J. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer Cancer Res. 2012, 72 (14) 3457-3462
19. Mostaghel, E. A.; Marck, B. T.; Plymate, S. R.; Vessella, R. L.; Balk, S.; Matsumoto, A. M.; Nelson, P. S.; Montgomery, R. B. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants Clin. Cancer Res. 2011, 17 (18) 5913-5925
20. Attard, G.; Cooper, C. S.; de Bono, J. S. Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell 2009, 16 (6) 458-462
21. Godbole, A. M. N.; V., C. O. New insights into the androgen-theargeted therapies and epigenetic therapies in prostate cancer Prostate Cancer 2011, 2011, 1-13
22. Godbole, A. M.; Njar, V. C. O. Prostate Cancer: Current and Emerging Therapies. In Current Cancer Treatment: Novel Beyond Conventional Approaches; Özdemir, Ö., Ed.; InTech: Rijika, Croatia, 2011; Chapter 14.
23. Wang, Q.; Li, W.; Zhang, Y.; Yuan, X.; Xu, K.; Yu, J.; Chen, Z.; Beroukhim, R.; Wang, H.; Lupien, M.; Wu, T.; Regan, M. M.; Meyer, C. A.; Carroll, J. S.; Manrai, A. K.; Janne, O. A.; Balk, S. P.; Mehra, R.; Han, B.; Chinnaiyan, A. M.; Rubin, M. A.; True, L.; Fiorentino, M.; Fiore, C.; Loda, M.; Kantoff, P. W.; Liu, X. S.; Brown, M. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer Cell 2009, 138 (2) 245-256
24. Handratta, V. D.; Vasaitis, T. S.; Njar, V. C.; Gediya, L. K.; Kataria, R.; Chopra, P.; Newman, D., Jr.; Farquhar, R.; Guo, Z.; Qiu, Y.; Brodie, A. M. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model J. Med. Chem. 2005, 48 (8) 2972-2984
25. Schayowitz, A.; Sabnis, G.; Goloubeva, O.; Njar, V. C.; Brodie, A. M. Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR Br. J. Cancer 2010, 103 (7) 1001-1007
26. Schayowitz, A.; Sabnis, G.; Njar, V. C.; Brodie, A. M. Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro Mol. Cancer Ther. 2008, 7 (1) 121-132
27. Vasaitis, T.; Belosay, A.; Schayowitz, A.; Khandelwal, A.; Chopra, P.; Gediya, L. K.; Guo, Z.; Fang, H. B.; Njar, V. C.; Brodie, A. M. Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}- hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1 H -benzimidazole-1-yl) androsta-5,16-diene in prostate cancer Mol. Cancer Ther. 2008, 7 (8) 2348-2357
28. Pereira de Jesus-Tran, K.; Cote, P. L.; Cantin, L.; Blanchet, J.; Labrie, F.; Breton, R. Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity Protein Sci. 2006, 15 (5) 987-999
29. Pike, A. C.; Brzozowski, A. M.; Walton, J.; Hubbard, R. E.; Thorsell, A. G.; Li, Y. L. Structural insights into the mode of action of a pure antiestrogen Structure 2001, 9 (2) 145-153
30. Wu, Y. L.; Yang, X.; Ren, Z.; McDonnell, D. P.; Norris, J. D.; Willson, T. M. Structural basis for an unexpected mode of SERM-mediated ER antagonism Mol Cell. 2005, 18 (4) 413-424
31. Puranik, P. P.; Godbole, A. M.; Gediya, L. K.; Ates-Alagoz, Z.; Njar, V. C. O. Exploitation of Multitarget Prostate Cancer Clinical Candidate VN/124-1 (TOK-001) To Develop a Novel Class of Androgen Receptor Down Regulating Agents for Prostate Cancer Therapy. Presented at the 242nd National Meeting of the American Chemical Society, Denver, CO, U.S., Aug 28-Sept 1, 2011; MEDI 35.
32. Fan, M.; Rickert, E. L.; Chen, L.; Aftab, S. A.; Nephew, K. P.; Weatherman, R. V. Characterization of molecular and structural determinants of selective estrogen receptor downregulators Breast Cancer Res. Treat. 2007, 103 (1) 37-44
33. Hanson, R. N.; McCaskill, E.; Tongcharoensirikul, P.; Dilis, R.; Labaree, D.; Hochberg, R. B. Synthesis and evaluation of 17alpha-(dimethylphenyl)vinyl estradiols as probes of the estrogen receptor-alpha ligand binding domain Steroids 2012, 77 (5) 471-476
34. Bissantz, C.; Kuhn, B.; Stahl, M. A medicinal chemist's guide to molecular interactions J. Med. Chem. 2010, 53 (14) 5061-5084
35. Liu, W.; Zhou, J.; Geng, G.; Shi, Q.; Sauriol, F.; Wu, J. H. Antiandrogenic, maspin induction, and antiprostate cancer activities of tanshinone IIA and its novel derivatives with modification in ring A J. Med. Chem. 2012, 55 (2) 971-975
36. Yang, J.; Wei, S.; Wang, D. S.; Wang, Y. C.; Kulp, S. K.; Chen, C. S. Pharmacological exploitation of the peroxisome proliferator-activated receptor gamma agonist ciglitazone to develop a novel class of androgen receptor-ablative agents J. Med. Chem. 2008, 51 (7) 2100-2107
37. Roy, J.; Breton, R.; Martel, C.; Labrie, F.; Poirier, D. Chemical synthesis and biological activities of 16alpha-derivatives of 5alpha-androstane-3alpha,17beta-diol as antiandrogens Bioorg. Med. Chem. 2007, 15 (8) 3003-3018
38. Pereira de Jesus-Tran, K.; Cote, P. L.; Cantin, L.; Blanchet, J.; Labrie, F.; Breton, R. Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity Protein Sci. 2006, 15 (5) 987-999
39. Njar, V. C.; Kato, K.; Nnane, I. P.; Grigoryev, D. N.; Long, B. J.; Brodie, A. M. Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 alpha-hydroxylase-C17,20-lyase (P450(17) alpha): potential agents for the treatment of prostate cancer J. Med. Chem. 1998, 41 (6) 902-912
40. Brik, A.; Wu, C. Y.; Best, M. D.; Wong, C. H. Tetrabutylammonium fluoride-assisted rapid N9-alkylation on purine ring: application to combinatorial reactions in microtiter plates for the discovery of potent sulfotransferase inhibitors in situ Bioorg. Med. Chem. 2005, 13 (15) 4622-4626
41. Devlin, T. A.; Jebaratnam, D. J. An improved procedure for the synthesis of 1,3-dideazaadenosine Syn Comm 1995, 25 (5) 711-718
42. Purushottamachar, P.; Khandelwal, A.; Vasaitis, T. S.; Bruno, R. D.; Gediya, L. K.; Njar, V. C. Potent anti-prostate cancer agents derived from a novel androgen receptor down-regulating agent Bioorg. Med. Chem. 2008, 16 (7) 3519-3529
43. Calogeropoulou, T.; Avlonitis, N.; Minas, V.; Alexi, X.; Pantzou, A.; Charalampopoulos, I.; Zervou, M.; Vergou, V.; Katsanou, E. S.; Lazaridis, I.; Alexis, M. N.; Gravanis, A. Novel dehydroepiandrosterone derivatives with antiapoptotic, neuroprotective activity J. Med. Chem. 2009, 52 (21) 6569-6587
44. Holland, H. L.; Kumaresan, S.; Tan, L.; Njar, V. C. O. Synthesis of 6-hydroxyimino-3-oxo steroids, a new class of aromatase inhibitors J. Chem. Soc., Perkin Trans. 1 1992, 585-587
45. Yamashita, K.; Kobayashi, S.; Tsukamoto, S.; Numazawa, M. Synthesis of pyridine-carboxylate derivatives of hydroxysteroids for liquid chromatography-electrospray ionization-mass spectrometry Steroids 2007, 72 (1) 50-59
46. Qian, K.; Kim, S. Y.; Hung, H. Y.; Huang, L.; Chen, C. H.; Lee, K. H. New betulinic acid derivatives as potent proteasome inhibitors Bioorg. Med. Chem. Lett. 2011, 21 (19) 5944-5947
47. Moreira, V. M.; Vasaitis, T. S.; Guo, Z.; Njar, V. C.; Salvador, J. A. Synthesis of novel C17 steroidal carbamates. Studies on CYP17 action, androgen receptor binding and function, and prostate cancer cell growth Steroids 2008, 73 (12) 1217-1227
48. Davenport, A. P.; Russell, F. D. Radioligand Binding Assays: Theory and Practice. In Current Directions in Radiopharmaceutical Research and Development; Mather, S. J., Ed.; Kluwer Academic Publishers: Dordrecht, The Netherlands, 1996.
49. Soifer, H. S.; Souleimanian, N.; Wu, S.; Voskresenskiy, A. M.; Collak, F. K.; Cinar, B.; Stein, C. A. Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells J. Biol. Chem. 2012, 287 (6) 3777-3787
50. Bradbury, R. H.; Hales, N. J.; Rabow, A. A.; Walker, G. E.; Acton, D. G.; Andrews, D. M.; Ballard, P.; Brooks, N. A.; Colclough, N.; Girdwood, A.; Hancox, U. J.; Jones, O.; Jude, D.; Loddick, S. A.; Mortlock, A. A. Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer Bioorg. Med. Chem. Lett. 2011, 21 (18) 5442-5445
51. Dehm, S. M.; Schmidt, L. J.; Heemers, H. V.; Vessella, R. L.; Tindall, D. J. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance Cancer Res. 2008, 68 (13) 5469-5477
52. Guo, Z.; Qiu, Y. A new trick of an old molecule: androgen receptor splice variants taking the stage?! Int. J. Biol. Sci. 2011, 7 (6) 815-822
53. Guo, Z.; Yang, X.; Sun, F.; Jiang, R.; Linn, D. E.; Chen, H.; Chen, H.; Kong, X.; Melamed, J.; Tepper, C. G.; Kung, H. J.; Brodie, A. M.; Edwards, J.; Qiu, Y. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth Cancer Res. 2009, 69 (6) 2305-2313
54. Hu, R.; Dunn, T. A.; Wei, S.; Isharwal, S.; Veltri, R. W.; Humphreys, E.; Han, M.; Partin, A. W.; Vessella, R. L.; Isaacs, W. B.; Bova, G. S.; Luo, J. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer Cancer Res. 2009, 69 (1) 16-22
55. Sun, S.; Sprenger, C. C.; Vessella, R. L.; Haugk, K.; Soriano, K.; Mostaghel, E. A.; Page, S. T.; Coleman, I. M.; Nguyen, H. M.; Sun, H.; Nelson, P. S.; Plymate, S. R. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant J. Clin. Invest. 2010, 120 (8) 2715-2730
56. Watson, P. A.; Chen, Y. F.; Balbas, M. D.; Wongvipat, J.; Socci, N. D.; Viale, A.; Kim, K.; Sawyers, C. L. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor Proc. Natl. Acad. Sci. U.S.A. 2010, 107 (39) 16759-65
57. Cao, B.; Liu, X.; Li, J.; Liu, S.; Qi, Y.; Xiong, Z.; Zhang, A.; Wiese, T.; Fu, X.; Gu, J.; Rennie, P. S.; Sartor, O.; Lee, B. R.; Ip, C.; Zhao, L.; Zhang, H.; Dong, Y. 20(S)-Protopanaxadiol-aglycone downregulation of the full-length and splice variants of androgen receptor Int. J. Cancer 2013, 132, 1277-1287
58. Li, J.; Cao, B.; Liu, X.; Fu, X.; Xiong, Z.; Chen, L.; Sartor, O.; Dong, Y.; Zhang, H. Berberine suppresses androgen receptor signaling in prostate cancer Mol. Cancer Ther. 2011, 10 (8) 1346-1356
59. Li, X.; Liu, Z.; Xu, X.; Blair, C. A.; Sun, Z.; Xie, J.; Lilly, M. B.; Zi, X. Kava components down-regulate expression of AR and AR splice variants and reduce growth in patient-derived prostate cancer xenografts in mice PLoS One 2012, 7 (2) e31213
60. Mashima, T.; Okabe, S.; Seimiya, H. Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth Mol. Pharmacol. 2010, 78 (5) 846-854
61. Yamashita, S.; Lai, K. P.; Chuang, K. L.; Xu, D.; Miyamoto, H.; Tochigi, T.; Pang, S. T.; Li, L.; Arai, Y.; Kung, H. J.; Yeh, S.; Chang, C. ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors Neoplasia 2012, 14 (1) 74-83
62. Haile, S.; Sadar, M. D. Androgen receptor and its splice variants in prostate cancer Cell. Mol. Life Sci. 2011, 68 (24) 3971-3981
63. Sadar, M. D. Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity Cancer Res. 2011, 71 (4) 1208-1213
64. DeVore, N. M.; Scott, E. E. Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001 Nature 2012, 482 (7383) 116-119
65. Njar, V. C.; Klus, G. T.; Brodie, A. Nucleophilic vinylic "addition-elimination" substitution reaction of 3 beta-acetoaxy-17- chloro-16-formylandrosta-5,16-diene: a novel and general route to 17-substituted-delta-steroids. Part 1. Synthesis of novel 17-azolyl steroids; inhibitors of 17 alpha-hydroxylase/17,20-lyase (P45017alpha) Bioorg. Med. Chem. Lett. 1996, 2777-2782
66. Potter, G. A.; Barrie, S. E.; Jarman, M.; Rowlands, M. G. Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase) : potential agents for the treatment of prostatic cancer J. Med. Chem. 1995, 38 (13) 2463-2471
67. Paller, C. J.; Antonarakis, E. S. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer Drug Des. Dev. Ther. 2011, 5, 117-124
68. Vacondio, F.; Silva, C.; Mor, M.; Testa, B. Qualitative structure-metabolism relationships in the hydrolysis of carbamates Drug Metab. Rev. 2010, 42 (4) 551-589
69. Chassaing, C.; Berger, M.; Heckeroth, A.; Ilg, T.; Jaeger, M.; Kern, C.; Schmid, K.; Uphoff, M. Highly water-soluble prodrugs of anthelmintic benzimidazole carbamates: synthesis, pharmacodynamics, and pharmacokinetics J. Med. Chem. 2008, 51 (5) 1111-1114
70. Geary, T. G.; Conder, G. A.; Bishop, B. The changing landscape of antiparasitic drug discovery for veterinary medicine Trends Parasitol 2004, 20 (10) 449-455
71. Brandt, G. E.; Schmidt, M. D.; Prisinzano, T. E.; Blagg, B. S. Gedunin, a novel hsp90 inhibitor: semisynthesis of derivatives and preliminary structure-activity relationships J. Med. Chem. 2008, 51 (20) 6495-6502
72. Chaudhaery, S. S.; Roy, K. K.; Shakya, N.; Saxena, G.; Sammi, S. R.; Nazir, A.; Nath, C.; Saxena, A. K. Novel carbamates as orally active acetylcholinesterase inhibitors found to improve scopolamine-induced cognition impairment: pharmacophore-based virtual screening, synthesis, and pharmacology J. Med. Chem. 2010, 53 (17) 6490-6505
73. Balasubramanian, S.; Verner, E.; Buggy, J. J. Isoform-specific histone deacetylase inhibitors: the next step? Cancer Lett 2009, 280 (2) 211-221
74. Purushottamachar, P.; Njar, V. C. A new simple and high-yield synthesis of 5alpha-dihydrotestosterone (DHT), a potent androgen receptor agonist Steroids 2012, 77 (14) 1530-1534
75. Godbole, A. M.; Purushottamachar, P.; Martin, M. S.; Daskalakis, C.; Njar, V. C. Autophagy inhibition synergistically enhances anti-cancer efficacy of RAMBA, VN/12-1 in SKBR-3 cells and tumor xenografts Mol. Cancer Ther. 2012, 11, 898-908
76. Wong, C.; Kelce, W. R.; Sar, M.; Wilson, E. M. Androgen receptor antagonist versus agonist activities of the fungicide vinclozolin relative to hydroxyflutamide J. Biol. Chem. 1995, 270 (34) 19998-20003
77. Yarbrough, W. G.; Quarmby, V. E.; Simental, J. A.; Joseph, D. R.; Sar, M.; Lubahn, D. B.; Olsen, K. L.; French, F. S.; Wilson, E. M. A single base mutation in the androgen receptor gene causes androgen insensitivity in the testicular feminized rat J. Biol. Chem. 1990, 265 (15) 8893-8900
78. Berges, R. R.; Furuya, Y.; Remington, L.; English, H. F.; Jacks, T.; Isaacs, J. T. Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation Proc. Natl. Acad. Sci. U.S.A. 1993, 90 (19) 8910-8914